Onward Medical FIRST LOOK: BCI technology accepted in the FDA TAP program

Onward's BCI technology has been accepted into the FDA's new Total Product Lifecycle Advisory Program (TAP) to optimize the road to commercialisation. TAP further builds on Breakthrough Device Designation and allows early and frequent strategic engagement from FDA and non-FDA stakeholders. We see Onward's acceptance as a validation of its ARCIM-BCI technology potential and the rising interest in the space. We re-iterate our € 10 TP and Buy rating.